Umang Vohra Appointed Chairman & Group CEO of Cohance Lifesciences
Corporate governance document open to executive remuneration details with a pen
Key Highlights
Cohance Lifesciences shareholders approve Umang Vohra as Chairman & Group CEO from May 2026. New ESOP sanctioned, but Vohra’s remuneration faces dissent.
Cohance Lifesciences Names Umang Vohra Chairman & Group CEO
Cohance Lifesciences Limited shareholders have approved the appointment of Mr. Umang Vohra as Chairman and Group Chief Executive Officer, effective May 2026. This significant leadership change follows a recent postal ballot.
The ballot results, declared on June 14, 2026, also sanctioned a new Employee Stock Option Plan, 2026, which extends to unlisted subsidiary companies. However, the remuneration package for Mr. Vohra, exceeding limits under Section 197 of the Companies Act, 2013, faced notable opposition.
Key Approvals & Shareholder Dissent
The remote e-voting process, managed by KFin Technologies Limited, ran from May 15 to June 13, 2026. While resolutions passed with the required majority, public institutional shareholders showed significant dissent.
- Mr. Umang Vohra (DIN: 02296740) is appointed Chairman effective May 1, 2026.
- He will also serve as Group Chief Executive Officer from May 20, 2026.
- The ‘Cohance Lifesciences Limited – Employee Stock Option Plan, 2026’ was approved.
- Shareholders authorized granting stock options equal to or exceeding 1% of the issued capital in a single financial year.
- institutional shareholders notably opposed the remuneration and stock option grant proposals.
Next Steps
The detailed scrutinizer’s report, prepared by Mr. DVM Gopal of M/s. DVM & Associates LLP, is now available on the company’s website. The record date for determining eligibility was May 8, 2026.